Compare Stocks: BMRN, NTRA, RVMD, and ALNY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$266.11 +0.6%	$259.25	$197.81 ▼ $495.55	$35.61B	0.31	1.72 million shs	1.43 million shs
BMRN BioMarin Pharmaceutical	$66.53 +0.2%	$62.58	$49.26 ▼ $70.98	$12.88B	0.24	2.24 million shs	2.30 million shs
NTRA Natera	$328.18 +0.2%	$292.62	$157.43 ▼ $343.18	$47.31B	1.54	1.40 million shs	968,061 shs
RVMD Revolution Medicines	$210.02 -0.4%	$196.93	$39.17 ▼ $224.31	$45.01B	1.4	1.80 million shs	884,506 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+12.24%	+23.13%	-12.19%	-40.52%
BMRN BioMarin Pharmaceutical	0.00%	+2.88%	+8.25%	+17.19%	+12.80%
NTRA Natera	0.00%	+0.59%	+23.66%	+52.42%	+95.89%
RVMD Revolution Medicines	0.00%	+1.03%	+6.17%	+40.74%	+428.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$266.11 +0.6%	$259.25	$197.81 ▼ $495.55	$35.61B	0.31	1.72 million shs	1.43 million shs
BMRN BioMarin Pharmaceutical	$66.53 +0.2%	$62.58	$49.26 ▼ $70.98	$12.88B	0.24	2.24 million shs	2.30 million shs
NTRA Natera	$328.18 +0.2%	$292.62	$157.43 ▼ $343.18	$47.31B	1.54	1.40 million shs	968,061 shs
RVMD Revolution Medicines	$210.02 -0.4%	$196.93	$39.17 ▼ $224.31	$45.01B	1.4	1.80 million shs	884,506 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+12.24%	+23.13%	-12.19%	-40.52%
BMRN BioMarin Pharmaceutical	0.00%	+2.88%	+8.25%	+17.19%	+12.80%
NTRA Natera	0.00%	+0.59%	+23.66%	+52.42%	+95.89%
RVMD Revolution Medicines	0.00%	+1.03%	+6.17%	+40.74%	+428.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.88	Moderate Buy	$386.14	45.10% Upside
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$89.17	34.04% Upside
NTRA Natera	2.82	Moderate Buy	$319.38	-2.68% Downside
RVMD Revolution Medicines	2.95	Moderate Buy	$200.74	-4.42% Downside

Current Analyst Ratings Breakdown

Latest BMRN, NTRA, RVMD, and ALNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/2/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$455.00
9/1/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$88.00 ➝ $90.00
8/31/2026	ALNY Alnylam Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	ALNY Alnylam Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	BMRN BioMarin Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $105.00
8/31/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$59.00 ➝ $60.00
8/31/2026	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$240.00 ➝ $275.00
8/28/2026	RVMD Revolution Medicines	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$220.00 ➝ $265.00
8/28/2026	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$240.00 ➝ $275.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	9.59	$2.80 per share	95.17	$10.12 per share	26.30
BMRN BioMarin Pharmaceutical	$3.22B	4.00	$2.85 per share	23.32	$32.66 per share	2.04
NTRA Natera	$2.31B	20.51	N/A	N/A	$12.64 per share	25.96
RVMD Revolution Medicines	$11.58M	3,887.37	N/A	N/A	$12.16 per share	17.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	49.46	27.43	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	179.81	12.21	0.48	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	32,818.00	N/A	-7.11%	-11.38%	-7.87%	11/5/2026 (Estimated)
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	11/4/2026 (Estimated)

Latest BMRN, NTRA, RVMD, and ALNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
NTRA Natera	N/A	3.00	2.85
RVMD Revolution Medicines	0.40	11.38	11.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BMRN BioMarin Pharmaceutical	98.71%
NTRA Natera	99.90%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BMRN BioMarin Pharmaceutical	0.68%
NTRA Natera	5.05%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
RVMD Revolution Medicines	250	214.34 million	198.05 million	Optionable

BMRN, NTRA, RVMD, and ALNY Headlines

Recent News About These Companies

Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval

September 5 at 12:42 PM | finance.yahoo.com

Raiffeisen Bank International AG Decreases Stake in Revolution Medicines, Inc. $RVMD

September 5 at 5:27 AM | marketbeat.com

Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?

September 4 at 12:37 PM | zacks.com

Revolution Medicines Got Its Breakthrough—What Moves It Next?

...

September 4 at 10:20 AM | marketbeat.com

Lorence Kim Sells 56,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

September 4 at 4:41 AM | americanbankingnews.com

Corient Private Wealth LP Acquires New Stake in Revolution Medicines, Inc. $RVMD

September 4 at 3:51 AM | marketbeat.com

J.P. Morgan Sticks to Their Buy Rating for Revolution Medicines (RVMD)

September 3 at 10:44 PM | theglobeandmail.com

Revolution Medicines Highlights NEJM Publication Of RASONQUE Lung Cancer Data

September 3 at 7:43 AM | rttnews.com

Revolution Medicines (NASDAQ:RVMD) Director Lorence Kim Sells 56,000 Shares

September 3 at 6:06 AM | insidertrades.com

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

September 2, 2026 | globenewswire.com

Insider Selling: Revolution Medicines (NASDAQ:RVMD) Director Sells $11,381,440.00 in Stock

September 2, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Revolution Medicines (RVMD)

September 2, 2026 | theglobeandmail.com

Revolution Medicines, Inc. $RVMD Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 2, 2026 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

September 2, 2026 | americanbankingnews.com

Revolution Medicines: Benefit Vs. Reality Compared To Peer Therapeutics

September 1, 2026 | seekingalpha.com

Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $275.00

August 31, 2026 | marketbeat.com

Moore Capital Management LP Has $15.30 Million Holdings in Revolution Medicines, Inc. $RVMD

August 31, 2026 | marketbeat.com

Public Employees Retirement System of Ohio Buys Shares of 77,402 Revolution Medicines, Inc. $RVMD

August 31, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Outlook for RVMD Earnings

August 31, 2026 | americanbankingnews.com

HC Wainwright Has Pessimistic Outlook of RVMD Q3 Earnings

August 31, 2026 | marketbeat.com

Patients with the deadliest cancer finally have something that works

August 30, 2026 | malaysia.news.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BMRN, NTRA, RVMD, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$266.11 +1.61 (+0.61%)

As of 09/4/2026 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical NASDAQ:BMRN

$66.53 +0.10 (+0.15%)

As of 09/4/2026 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Natera NASDAQ:NTRA

$328.18 +0.51 (+0.16%)

As of 09/4/2026 04:00 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines NASDAQ:RVMD

$210.02 -0.85 (-0.40%)

As of 09/4/2026 04:00 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMRN, NTRA, RVMD, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMRN, NTRA, RVMD, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMRN, NTRA, RVMD, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMRN, NTRA, RVMD, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

BioMarin Pharmaceutical NASDAQ:BMRN

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMRN, NTRA, RVMD, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMRN, NTRA, RVMD, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMRN, NTRA, RVMD, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMRN, NTRA, RVMD, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

BioMarin Pharmaceutical NASDAQ:BMRN

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools